FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Martine Piccart

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Sherene Loi; Stefan Michiels; Martine J Piccart; Fanny Piette; Emmanuel Quinaux; Ghizlane Rouas; Roberto Salgado; Nicolas Sirtaine; John P A Crown; Evandro de Azambuja; Angelo Di Leo; Prudence Francis; Erika Hitre; Françoise Van Eenoo; Giuseppe Viale; C Sotiriou
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Sherene Loi; Stefan Michiels; Martine J Piccart; Vicky S Sabine; Tarek Sahmoud; Andrew H Sims; Sandeep K Singhal; John M S Bartlett; Jose Baselga; J Michael Dixon; C Sotiriou
PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.
Hatem A Azim; Octavi Cordoba; Evandro de Azambuja; Leticia De Mattos-Arruda; Shari Gelber; Aron Goldhirsch; Maj-Britt Jensen; Niels Kroman; Marianne Paesmans; Martine J Piccart; Alvaro Pinto; Barbara Pistilli; Nicole Rotmensz; Lieveke ameye; Fedro Alessandro Peccatori
Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Martine Piccart (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Sherene Loi; Stefan Michiels; Martine J Piccart; Fanny Piette; Emmanuel Quinaux; Ghizlane Rouas; Roberto Salgado; Nicolas Sirtaine; John P A Crown; Evandro de Azambuja; Angelo Di Leo; Prudence Francis; Erika Hitre; Françoise Van Eenoo; Giuseppe Viale; C Sotiriou
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(7):860-7.
2013: Sherene Loi; Stefan Michiels; Martine J Piccart; Vicky S Sabine; Tarek Sahmoud; Andrew H Sims; Sandeep K Singhal; John M S Bartlett; Jose Baselga; J Michael Dixon; C Sotiriou
PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.
PloS one 2013;8(1):e53292.
2013: Hatem A Azim; Octavi Cordoba; Evandro de Azambuja; Leticia De Mattos-Arruda; Shari Gelber; Aron Goldhirsch; Maj-Britt Jensen; Niels Kroman; Marianne Paesmans; Martine J Piccart; Alvaro Pinto; Barbara Pistilli; Nicole Rotmensz; Lieveke ameye; Fedro Alessandro Peccatori
Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(1):73-9.
2012: Martine J Piccart
Triple-negative breast cancer in focus: from biology to novel therapeutics. Editorial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23 Suppl 6():vi5-6.
2011: Sherene Loi; Lina Pugliano; C Sotiriou; Evandro de Azambuja; Martine J Piccart
HER2-overexpressing breast cancer: time for the cure with less chemotherapy?
Current opinion in oncology 2011;23(6):547-58.
2011: H A Azim; J Bines; Mariantonietta Colozza; Evandro de Azambuja; Martine J Piccart
Long-term toxic effects of adjuvant chemotherapy in breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(9):1939-47.
2011: Marcin Sinacki; Andrzej Badzio; Marzena Wełnicka-Jaśkiewicz; Jan Bogaerts; Martine J Piccart; Patrick Therasse; Ian E Smith; Thomas Hatschek; Jacek Jassem
Pattern of care in locally advanced breast cancer: focus on local therapy.
Breast (Edinburgh, Scotland) 2011;20(2):145-50.
2011: Hatem A Azim; Fedro Alessandro Peccatori; Evandro de Azambuja; Martine J Piccart
Motherhood after breast cancer: searching for la dolce vita.
Expert review of anticancer therapy 2011;11(2):287-98.
2010: Hatem A Azim; Martine J Piccart
Simultaneous targeting of estrogen receptor and HER2 in breast cancer.
Expert review of anticancer therapy 2010;10(8):1255-63.
2010: Sherene Loi; Benjamin Haibe-Kains; Samira Majjaj; Francoise Lallemand; Virginie Durbecq; Denis Larsimont; Ana M Gonzalez-Angulo; Lajos Pusztai; W Fraser Symmans; Alberto Bardelli; Paul Ellis; Andrew N J Tutt; Cheryl E Gillett; Bryan T Hennessy; Gordon B Mills; Wayne A Phillips; Martine J Piccart; Terence P Speed; Grant A McArthur; C Sotiriou
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.
Proceedings of the National Academy of Sciences of the United States of America 2010;107(22):10208-13.
2009: Sherene Loi; Christos Sotiriou; Benjamin Haibe-Kains; Francoise Lallemand; Nelly M Conus; Martine J Piccart; Terence P Speed; Grant A McArthur
Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer.
BMC medical genomics 2009;2():37.
2008: Daniela D Rosa; Ahmad Awada; Max S Mano; Jean Selleslags; Fabienne Lebrun; Thierry Gil; Martine J Piccart; Véronique D'Hondt
Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma.
Archives of gynecology and obstetrics 2008;278(5):457-62.
2008: Robert Paridaens; Luc Y Dirix; Louk V Beex; Marianne Nooij; David A Cameron; Tanja Cufer; Martine J Piccart; Jan Bogaerts; Patrick Therasse
Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(30):4883-90.
2008: Carlos M Galmarini; Isabelle Treilleux; Fatima Cardoso; Chantal Bernard-Marty; Virginie Durbecq; David Gancberg; Marie Christine Bissery; Marianne Paesmans; Denis Larsimont; Martine J Piccart; Angelo Di Leo; Charles Dumontet
Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(14):4511-6.
2008: Irene L Wapnir; Stefan Aebi; Charles E Geyer; David Zahrieh; Richard D Gelber; Stewart J Anderson; Andre Robidoux; Jürg Bernhard; Rudolf Maibach; Monica Castiglione-Gertsch; Alan Coates; Martine J Piccart; Mark J Clemons; Joseph P Costantino; Norman Wolmark
A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37.
Clinical breast cancer 2008;8(3):287-92.
2008: James N Ingle; Dongsheng Tu; Joseph L Pater; Hyman Muss; Silvana Martino; Nicholas J Robert; Martine J Piccart; M Castiglione; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; David A Cameron; Michael J Palmer; Paul E Goss
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(5):877-82.
2008: Paul E Goss; James N Ingle; Joseph L Pater; Silvana Martino; Nicholas J Robert; Hyman Muss; Martine J Piccart; Monica Castiglione; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; David A Cameron; Michael J Palmer; Dongsheng Tu
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(12):1948-55.
2008: Hyman Muss; Dongsheng Tu; James N Ingle; Silvana Martino; Nicholas J Robert; Joseph L Pater; Timothy J Whelan; Michael J Palmer; Martine J Piccart; Lois E Shepherd; Kathleen I Pritchard; Zhi He; Paul E Goss
Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(12):1956-64.
2008: Nicolas Whenham; Véronique D'Hondt; Martine J Piccart
HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies.
Clinical breast cancer 2008;8(1):38-49.
2008: Sherene Loi; Benjamin Haibe-Kains; Christine Desmedt; Pratyaksha Wirapati; Françoise Lallemand; Andrew M Tutt; Cheryl Gillet; Paul Ellis; Kenneth Ryder; James F Reid; Maria G Daidone; Marco A Pierotti; Petronella Berns; maurice jansen; John A Foekens; Mauro Delorenzi; Gianluca Bontempi; Martine J Piccart; C Sotiriou
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.
BMC genomics 2008;9():239.
2007: Christos Sotiriou; Martine J Piccart
Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?
Nature reviews. Cancer 2007;7(7):545-53.
2007: Mariantonietta Colozza; Evandro de Azambuja; Nicola Personeni; Fabienne Lebrun; Martine J Piccart; Fatima Cardoso
Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.
The oncologist 2007;12(3):253-70.
2007: Rosa Giuliani; Virginie Durbecq; Angelo Di Leo; Marianne Paesmans; Denis Larsimont; Jean-Yves Leroy; Marleen Borms; Anita Vindevoghel; Guy Jerusalem; Véronique D'Hondt; Luc Dirix; Jean-Luc Canon; Vincent Richard; Veronique Cocquyt; Françoise Majois; Michel Reginster; Jan Demol; Jean-Pierre Kains; Paul Delree; Carine Keppens; Christos Sotiriou; Martine J Piccart; Fatima Cardoso
Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).
European journal of cancer (Oxford, England : 1990) 2007;43(4):725-35.
2006: Chantal Bernard-Marty; Fatima Cardoso; Christos Sotiriou; Martine J Piccart
[Towards an individualization of systemic treatment of breast tumors].
Bulletin du cancer 2006;93(8):791-7.
2006: Evandro Azambuja; Martine J Piccart; Ahmad Awada
Long-term survival in pituitary metastasis from breast cancer.
Breast (Edinburgh, Scotland) 2006;15(3):446-7.
2006: Mariantonietta Colozza; Evandro de Azambuja; Fatima Cardoso; Chantal Bernard; Martine J Piccart
Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.
The oncologist 2006;11(2):111-25.
2006: Chantal Bernard-Marty; Fabienne Lebrun; Ahmad Awada; Martine J Piccart
Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions.
Drugs 2006;66(12):1577-91.
2006: Gordon J S Rustin; Petra Timmers; Ann Nelstrop; Gavin Shreeves; Soeren M Bentzen; Benoit Baron; Martine J Piccart; Kamma Bertelsen; Gavin Stuart; James Cassidy; Elizabeth Eisenhauer
Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(1):45-51.
2005: Martine J Piccart; Dominique de Valeriola; L Dal Lago; Evandro de Azambuja; Gaston Demonty; Fabienne Lebrun; Chantal Bernard-Marty; Mariantonietta Colozza; T Cufer
Adjuvant chemotherapy in 2005: standards and beyond.
Breast (Edinburgh, Scotland) 2005;14(6):439-45.
2005: Mariantonietta Colozza; Evandro Azambuja; Fatima Cardoso; Christos Sotiriou; Denis Larsimont; Martine J Piccart
Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(11):1723-39.
2005: Mariantonietta Colozza; Denis Larsimont; Martine J Piccart
Progesterone receptor testing: not the right time to be buried.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(16):3867-8; author reply 3869-70.
2005: Mariantonietta Colozza; Fatima Cardoso; Christos Sotiriou; Denis Larsimont; Martine J Piccart
Bringing molecular prognosis and prediction to the clinic.
Clinical breast cancer 2005;6(1):61-76.
2004: Fatima Cardoso; Marianne Paesmans; Denis Larsimont; Virginie Durbecq; Chantal Bernard-Marty; Ghizlane Rouas; Stella Dolci; Christos Sotiriou; Martine J Piccart; Angelo Di Leo
Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer.
Clinical breast cancer 2004;5(5):364-9.
2004: Fabio Efficace; Patrick Therasse; Martine J Piccart; Corneel Coens; Kristel van Steen; Marzena Welnicka-Jaskiewicz; Tanja Cufer; Jaroslaw Dyczka; Michail R Lichinitser; Lois Shepherd; Hanneke de Haes; Mirjam A G Sprangers; andrew bottomley
Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(16):3381-8.
2004: Angelo Di Leo; S Chan; Marianne Paesmans; Kay Friedrichs; T Pinter; Veronique Cocquyt; E Murray; István Bodrogi; Euan Walpole; B Lesperance; Stefan Korec; J Crown; P Simmonds; Gunter von Minckwitz; Jean-Yves Leroy; Virginie Durbecq; Jorma Isola; M Aapro; Martine J Piccart; Denis Larsimont
HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.
Breast cancer research and treatment 2004;86(3):197-206.
2004: Ahmad Awada; Thierry Gil; François Sales; M Dubuisson; Pierre Vereecken; J Klastersky; C Moerman; Dominique de Valeriola; Martine J Piccart
Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers.
Anti-cancer drugs 2004;15(5):499-502.
2004: Laura Biganzoli; Aron Goldhirsch; C Straehle; M Castiglione-Gertsch; Patrick Therasse; Matti Aapro; Alessandro Marco Minisini; Martine J Piccart
Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group (BIG).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(2):207-10.
2004: Chantal Bernard-Marty; Fatima Cardoso; Martine J Piccart
Facts and controversies in systemic treatment of metastatic breast cancer.
The oncologist 2004;9(6):617-32.
2004: Fatima Cardoso; Virginie Durbecq; Denis Larsimont; Marianne Paesmans; Jean-Yves Leroy; Ghizlane Rouas; Christos Sotiriou; N Renard; V Richard; Martine J Piccart; Angelo Di Leo
Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer.
International journal of oncology 2004;24(1):201-9.
2003: Fatima Cardoso; Martine J Piccart
The best use of chemotherapy in the adjuvant setting.
Breast (Edinburgh, Scotland) 2003;12(6):522-8.
2003: Martine J Piccart; Christos Sotiriou; Fatima Cardoso
New data on chemotherapy in the adjuvant setting.
Breast (Edinburgh, Scotland) 2003;12(6):373-8.
2003: Martine J Piccart; Kamma Bertelsen; G Stuart; J Cassidy; Costantino Mangioni; E Simonsen; K James; S Kaye; Ignace Vergote; R Blom; Robert Grimshaw; R Atkinson; kenneth d swenerton; C Trope; M Nardi; Janne Kaern; Salvatore Tumolo; Petra Timmers; Josee-Anne Roy; F Lhoas; B Lidvall; Monica Bacon; A Birt; J Andersen; Benny Zee; James Paul; Sergio Pecorelli; B Baron; W McGuire
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003;13 Suppl 2():144-8.
2003: Gul Atalay; Laura Biganzoli; F Renard; Robert Paridaens; Tanja Cufer; R Coleman; A H Calvert; Teresa Gamucci; Alessandro Marco Minisini; Patrick Therasse; Martine J Piccart
Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials.
European journal of cancer (Oxford, England : 1990) 2003;39(17):2439-49.
2003: A Awada; Fatima Cardoso; Gul Atalay; Rosa Giuliani; Max S Mano; Martine J Piccart
The pipeline of new anticancer agents for breast cancer treatment in 2003.
Critical reviews in oncology/hematology 2003;48(1):45-63.
2003: Chantal Bernard-Marty; Fatima Cardoso; Martine J Piccart
Use and abuse of taxanes in the management of metastatic breast cancer.
European journal of cancer (Oxford, England : 1990) 2003;39(14):1978-89.
2003: Gul Atalay; Fatima Cardoso; A Awada; Martine J Piccart
Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(9):1346-63.
2003: Fatima Cardoso; Caroline Lohrisch; Martine J Piccart
Landmark adjuvant randomized clinical trials of systemic therapy in early breast cancer.
Drugs of today (Barcelona, Spain : 1998) 2003;39(6):399-414.
2003: Chantal Bernard-Marty; M Mano; Marianne Paesmans; C Accettura; R Munoz-Bermeo; T Richard; K Kleiber; Fatima Cardoso; Jean-Pierre Lobelle; Denis Larsimont; Martine J Piccart; Angelo Di Leo
Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(5):693-8.
2003: Ahmad Awada; R Thödtmann; Martine J Piccart; Jantien Wanders; A H G J Schrijvers; I-M Von Broen; Axel R Hanauske
An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 2003;39(6):742-7.
2003: Patrick Therasse; Louis Mauriac; Marzena Welnicka-Jaskiewicz; Peter Bruning; Tanja Cufer; Hervé Bonnefoi; E Tomiak; K I Pritchard; A Hamilton; Martine J Piccart
Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(5):843-50.
2002: Chantal Bernard-Marty; Isabelle Treilleux; Charles Dumontet; Fatima Cardoso; Arlette Fellous; David Gancberg; Marie Christine Bissery; Marianne Paesmans; Denis Larsimont; Martine J Piccart; Angelo Di Leo
Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study.
Clinical breast cancer 2002;3(5):341-5.
2002: Fatima Cardoso; Angelo Di Leo; Martine J Piccart
Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer.
Cancer treatment reviews 2002;28(6):275-90.
2002: Martine J Piccart; Fatima Cardoso; Gul Atalay
Letrozole's superiority over progestins and tamoxifen challenges standards of care in endocrine therapy for metastatic breast cancer.
European journal of cancer (Oxford, England : 1990) 2002;38 Suppl 6():S52-4.
2002: Angelo Di Leo; Fatima Cardoso; Virginie Durbecq; Rosa Giuliani; Max S Mano; Gul Atalay; Denis Larsimont; Christos Sotiriou; Laura Biganzoli; Martine J Piccart
Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002.
International journal of clinical oncology 2002;7(4):245-53.
2002: Laura Biganzoli; Tanja Cufer; Peter Bruning; R Coleman; Luc Duchateau; A H Calvert; Teresa Gamucci; Chris Twelves; Pierre Fargeot; R Epelbaum; Caroline Lohrisch; Martine J Piccart
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(14):3114-21.
2002: David Gancberg; Tero Järvinen; Angelo Di Leo; Ghizlane Rouas; Fatima Cardoso; Marianne Paesmans; Alain Verhest; Martine J Piccart; Jorma Isola; Denis Larsimont
Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing.
Breast cancer research and treatment 2002;74(2):113-20.
2002: David Gancberg; Angelo Di Leo; Fatima Cardoso; Ghizlane Rouas; M Pedrocchi; Marianne Paesmans; Alain Verhest; Chantal Bernard-Marty; Martine J Piccart; Denis Larsimont
Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(7):1036-43.
2002: Denis Larsimont; Angelo Di Leo; Ghizlane Rouas; Marianne Paesmans; Fabiano Ferreira-Filho; Chantal Bernard; Fatima Cardoso; Alain Verhest; Martine J Piccart; David Gancberg
HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice.
Anticancer research 2002;22(4):2485-90.
2002: Antonio Fabiano Ferreira Filho; John Crown; Fatima Cardoso; Jean-Marie Nogaret; Karen Duffy; Stella Dolci; Susan Rowan; Niall O'Higgins; Veronique Batter; Marianne Paesmans; Martine J Piccart; Angelo Di Leo
3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.
Anticancer research 2002;22(4):2471-6.
2002: Angelo Di Leo; David Gancberg; Denis Larsimont; Minna Tanner; Tero Jarvinen; Ghizlane Rouas; Stella Dolci; Jean-Yves Leroy; Marianne Paesmans; Jorma Isola; Martine J Piccart
HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(5):1107-16.
2002: David Gancberg; Angelo Di Leo; Ghizlane Rouas; T Järvinen; Alain Verhest; Jorma Isola; Martine J Piccart; Denis Larsimont
Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma.
Journal of clinical pathology 2002;55(4):315-7.
2002: Antonio Fabiano Ferreira Filho; Angelo Di Leo; Marianne Paesmans; Marc Beauduin; Anita Vindevoghel; J Michel; Christian Focan; Ahmad Awada; Fatima Cardoso; Stella Dolci; S Bartholomeus; Martine J Piccart
The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(3):416-21.
2002: Fatima Cardoso; Leo A Di; Caroline Lohrisch; C Bernard; F Ferreira; Martine J Piccart
Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(2):197-207.
2001: Caroline Lohrisch; Martine J Piccart
Standard medical treatment for early breast cancer.
European journal of cancer (Oxford, England : 1990) 2001;37 Suppl 7():S45-58.
2001: Martine J Piccart; H Lamb; J B Vermorken
Current and future potential roles of the platinum drugs in the treatment of ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(9):1195-203.
2001: Angelo Di Leo; Denis Larsimont; David Gancberg; T Jarvinen; Marc Beauduin; Anita Vindevoghel; J Michel; Christian Focan; F Ries; P H Gobert; MT Closon-Dejardin; Stella Dolci; Ghizlane Rouas; Marianne Paesmans; Jean-Pierre Lobelle; Jorma Isola; Martine J Piccart
HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(8):1081-9.
2001: Martine J Piccart; Angelo Di Leo; Marc Beauduin; Anita Vindevoghel; J Michel; Christian Focan; A Tagnon; F Ries; P Gobert; C Finet; MT Closon-Dejardin; J P Dufrane; Joseph Kerger; F Liebens; S Beauvois; S Bartholomeus; Stella Dolci; Jean-Pierre Lobelle; Marianne Paesmans; Jean-Marie Nogaret
Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(12):3103-10.
2001: Martine J Piccart; Caroline Lohrisch; Luc Duchateau; Marc Buyse
Taxanes in the adjuvant treatment of breast cancer: why not yet?
Journal of the National Cancer Institute. Monographs 2001;(30):88-95.
2001: Fatima Cardoso; Antonio Fabiano Ferreira Filho; John Crown; Stella Dolci; Marianne Paesmans; A Riva; Angelo Di Leo; Martine J Piccart
Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study.
Anticancer research 2001;21(1B):789-95.
2000: Minna Tanner; David Gancberg; Angelo Di Leo; Denis Larsimont; Ghizlane Rouas; Martine J Piccart; Jorma Isola
Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.
The American journal of pathology 2000;157(5):1467-72.
2000: Caroline Lohrisch; Martine J Piccart
Do we have good surrogate endpoints for survival in breast cancer studies?
Tumori 2000;86(5 Suppl 1):S4-10.
2000: Martine J Piccart; Kamma Bertelsen; K James; J Cassidy; Costantino Mangioni; E Simonsen; G Stuart; S Kaye; Ignace Vergote; R Blom; Robert Grimshaw; R J Atkinson; kenneth d swenerton; C Trope; M Nardi; Janne Kaern; Salvatore Tumolo; Petra Timmers; Josee-Anne Roy; F Lhoas; B Lindvall; Monica Bacon; A Birt; JE Andersen; Benny Zee; James Paul; B Baron; Sergio Pecorelli
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
Journal of the National Cancer Institute 2000;92(9):699-708.
2000: Angelo Di Leo; John Crown; Jean-Marie Nogaret; K Duffy; S Bartholomeus; Stella Dolci; S Rowan; N O'Higgins; Marianne Paesmans; Denis Larsimont; A Riva; Martine J Piccart
A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(2):169-75.
1999: Ahmad Awada; Cornelis J A Punt; Martine J Piccart; Olaf van Tellingen; L Van Manen; Joseph Kerger; Y Groot; Jantien Wanders; Jaap Verweij; D J Wagener
Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule.
British journal of cancer 1999;79(9-10):1454-61.
1999: Martine J Piccart; G C Stuart; J Cassidy; Kamma Bertelsen; M K B Parmar; Elizabeth A Eisenhauer; SB Kaye; Claes Tropé; kenneth d swenerton; P Harper; J B Vermorken
Intergroup collaboration in ovarian cancer: a giant step forward.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10 Suppl 1():83-6.
1999: Gordon J S Rustin; Ann Nelstrop; Soeren M Bentzen; Martine J Piccart; Kamma Bertelsen
Use of tumour markers in monitoring the course of ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10 Suppl 1():21-7.
1998: Peter Bruning; Johannes M G Bonfrer; Robert Paridaens; Marianne A Nooij; Jan G M Klijn; Louk V A M Beex; J Bruynseels; Martine J Piccart
Vorozole (R83842) in the treatment of postmenopausal advanced breast cancer: relationship of serum levels of vorozole and clinical results (a study of the EORTC Breast Cancer Cooperative Group).
Anti-cancer drugs 1998;9(5):419-25.
1998: Martine J Piccart
The changing landscape of breast cancer clinical research. ESMO-Award Lecture, ECCO-9 Hamburg, 18 September 1997.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(2):133-8.
1998: Olaf van Tellingen; Cornelis J A Punt; Ahmad Awada; D J Wagener; Martine J Piccart; Y Groot; L J Schaaf; RE Henrar; Willem Nooijen; Jos H Beijnen
A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study.
Cancer chemotherapy and pharmacology 1998;41(5):377-84.
1998: Robert Paridaens; Josee-Anne Roy; Marianne A Nooij; Jan G M Klijn; S J Houston; Louk V A M Beex; J Vinholes; E Tomiak; Ann Van Vreckem; C Langenaeken; Martine Van Glabbeke; Martine J Piccart
Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational Drug Branch of the European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Cooperative Group.
Anti-cancer drugs 1998;9(1):29-35.
1997: L Biganzoli; Martine J Piccart
The bigger the better? ... or what we know and what we still need to learn about anthracycline dose per course, dose density and cumulative dose in the treatment of breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(12):1177-82.
1997: Z Kusenda; Joseph Kerger; Ahmad Awada; F Geurs; Ann Van Vreckem; N Habboubi; Martine J Piccart
Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC).
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1997;5(5):414-6.
1997: Martine J Piccart; Jan G M Klijn; Robert Paridaens; Marianne A Nooij; Louis Mauriac; R Coleman; Marijke Bontenbal; Ahmad Awada; J Selleslags; Ann Van Vreckem; Martine Van Glabbeke
Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(9):3149-55.
1997: Ahmad Awada; Ann Van Vreckem; Robert Paridaens; Peter Bruning; Jan G M Klijn; E Tomiak; J Vinholes; Josee-Anne Roy; Z Kusenda; G Hoctin Boes; Martine Van Glabbeke; Martine J Piccart
EORTC-IDBBC (Investigational Drug Branch for Breast Cancer): 5 years of European collaboration in new drug development for breast cancer.
European journal of cancer (Oxford, England : 1990) 1997;33(8):1173-6.
1996: Martine J Piccart; L Biganzoli; Josee-Anne Roy
Adjuvant systemic therapy for breast cancer.
Current opinion in oncology 1996;8(6):478-84.
1996: Josee-Anne Roy; Martine J Piccart
[Systemic adjuvant therapy of breast cancer: myths and controversies].
Revue médicale de Bruxelles 1996;17(4):267-70.
1995: Josee-Anne Roy; Martine J Piccart
Adjuvant systemic therapy for breast cancer.
Current opinion in oncology 1995;7(6):517-22.
1995: Martine J Piccart; Peter Bruning; J Wildiers; Ahmad Awada; Jan H Schornagel; J Thomas; E Tomiak; S Bartholomeus; P O Witteveen; Robert Paridaens
An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(7):673-7.
1995: Josee-Anne Roy; Martine J Piccart
[Respective indications for hormone therapy, induction chemotherapy and adjuvant chemotherapy in breast cancer without clinically discernable distant metastases].
Revue médicale de Bruxelles 1995;16(4):242-4.
1995: Martine J Piccart; M Gore; W Ten Bokkel Huinink; A Van Oosterom; J Verweij; Jantien Wanders; H Franklin; M Bayssas; S Kaye
Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer.
Journal of the National Cancer Institute 1995;87(9):676-81.
1995: Martine J Piccart; E Raymond; M Aapro; Elizabeth A Eisenhauer; E Cvitkovic
Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: current status and future prospects.
European journal of cancer (Oxford, England : 1990) 1995;31A Suppl 7():S1-10.
1994: E Tomiak; Martine J Piccart; Joseph Kerger; S Lips; Ahmad Awada; D de Valeriola; C Ravoet; D Lossignol; Jean-Paul Sculier; V Auzannet
Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(7):1458-67.
1993: Robert F Ozols; J T Thigpen; J Dauplat; N Colombo; Martine J Piccart; Kamma Bertelsen; L Levin; B Lund
Advanced ovarian cancer. Dose intensity.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4 Suppl 4():49-56.
1993: Heine H Hansen; Elizabeth A Eisenhauer; M Hansen; J P Neijt; Martine J Piccart; C Sessa; J T Thigpen
New cytostatic drugs in ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4 Suppl 4():63-70.
1992: Stanley B Kaye; Jantien Wanders; M Clavel; Jaap Verweij; Martine J Piccart; J F Smyth; W W Ten Bokkel Huinink; D J Wagener; I R Judson; F Cavalli
Phase II trials of fosquidone (GR63178A) in carcinoma of the breast, head and neck, ovary and melanoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(5):406-8.
1992: Martine J Piccart; D de Valeriola; E Tomiak
Anthracyclines active via the oral route: luxury or necessity?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(3):181-2.
1992: Martine J Piccart; Joseph Kerger; E Tomiak; D J Perrault
Systemic treatment for locally advanced breast cancer: what we still need to learn after a decade of multimodality clinical trials.
European journal of cancer (Oxford, England : 1990) 1992;28(2-3):667-72.
1988: Martine J Piccart; D de Valeriola; Robert Paridaens; D Balikdjian; W H Mattheiem; C Loriaux; C Arrigo; F Cantraine; J C Heuson
Six-year results of a multimodality treatment strategy for locally advanced breast cancer.
Cancer 1988;62(12):2501-6.